IP Review

This fragment is not visible to the reader

This publication includes IP covered under the following statements.

This artifact includes content from International Standard Classification of Occupations (ISCO). ISCO is copyright International Labour Organization (ILO). Terms & Conditions in http://www.ilo.org/global/copyright/lang--en/index.htm
Show Usage
- International Standard Classification of Occupations (ISCO) : eHDSIHealthcareProfessionalRole
This material contains content from LOINC . LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license . LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
Show Usage
- LOINC: eHDSIBloodPressure , eHDSIDocumentCode ... Show 8 more
This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org .
Show Usage
- SNOMED Clinical Terms® (SNOMED CT®) : eHDSIAdverseEventType , eHDSIAllergenNoDrug ... Show 21 more
This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
Show Usage
Unless otherwise indicated, reproduction of material posted on Council of Europe websites, and reproduction of photographs for which the Council of Europe holds copyright – see legal notice \“photo credits\” – is authorised for private use and for informational and educational uses relating to the Council of Europe’s work. This authorisation is subject to the condition that the source be indicated and no charge made for reproduction. Persons wishing to make some other use than those specified above, including commercial use, of information and text posted on these sites are asked to apply for prior written authorisation to the Council of Europe, Directorate of Communication.
Show Usage
- EDQM Standard Terms : eHDSIDoseForm , eHDSIPackage , eHDSIQuantityUnit and eHDSIRouteofAdministration
WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.
Show Usage
- ATC classification system : eHDSIActiveIngredient and eHDSIVaccine

hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol ( src )

((R)-7-((1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl)amino)-2-(6-methoxypyridin-2-yl)pyrazolo [1,5-a]pyrimidine-6-carboxamide) ( src )

((Trans)-4-((2-(((2-chloro-4-((((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)carbamoyl)oxy)ethyl)(methyl)amino)cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate ( src )

(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate ( src )

(R)-(-)-N-(2-(3-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl)piperidino)ethyl)-4-fluorobenzamide ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone ( src )

(R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile ( src )

(R)-1-(1-Acryloylpiperidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide ( src )

(R)-1-(5-tert-butyl-indan-1-yl)-3-(1H-indazol-4-yl)-urea ( src )

(R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide ( src )

(R)-2-(4-(Cyclopropylsulfonyl)phenyl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide ( src )

(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-(1,2,4)triazolo(4,3-a)pyrimidin-5-yl)phenyl)-n,n,n-trimethylethanaminium methanesulfonate ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-[11C]methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-one ( src )

(R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phenylpropanamide ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate ( src )

(R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide ( src )

(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione ( src )

(R)-3-Chloro-1,2-propanediol ( src )

(R)-4-((3-(1H-Imidazol-1-yl)-6,6-dimethylcyclohex-2-en-1-yl)(methyl)amino)-2-(trifluoromethyl)benzonitrile ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one mesilate ( src )

(R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol ( src )

(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile ( src )

(R)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine ( src )

(R)-ALPHA-GLYCEROPHOSPHORYLETHANOLAMINE MONOHYDRATE ( src )

(R)-Bicalutamide ( src )

(R)-Deuteropioglitazone ( src )

(R)-Deuteropioglitazone hydrochloride ( src )

(R)-Glycidyl tosilate ( src )

(R)-Ketamine ( src )

(R)-Ketamine hydrochloride ( src )

(R)-Mequitazine ( src )

(R)-N-(1-(3-(Cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide ( src )

(R)-N-(1-carboxy-3-((phenylacetyl)amino)propyl)-L-leucyl-N,O-dimethyl-L-tyrosinamide ( src )

(R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide ( src )

(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide ( src )

(R)-Otenaproxesul ( src )

(R)-Styrene oxide ( src )

(R)-Warfarin ( src )

(R)-alpha-glycerophosphorylethanolamine ( src )

(R)-fadrozole phosphate ( src )

(R)-troloxamide quinone ( src )

(S)-4-(((R)-6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid ( src )

(r)-4-((4-(((4-(tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol ( src )

1-(4'-(3-methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid ( src )

2-((R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide ( src )

3-((S)-4-(5-((4-(4-chlorothiophen-2-yl)-5-(((R)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)carbamoyl)pyrazin-2-yl)-2-methylpiperazin-1-yl)propanoic acid ( src )

4-[(5-bromo-4-{[(R)-1-hydroxypropan-2-yl]amino}pyrimidin-2-yl)amino]benzenesulfonamide ( src )

4-[4-[(R)-[2-(4-Chlorophenyl)phenyl]-hydroxymethyl]piperidin-1-yl]-N-[4-[[(2R)-4-[2-hydroxyethyl(methyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide sesquifumarate ( src )

5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one ( src )

9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE, SODIUM SALT (1:2) ( src )

AMPHISOL® K ( src )

Bg sup(c) Ag [Presence] on Red Blood Cells ( src )

McC sup(c) Ab [Presence] in Serum or Plasma ( src )

Methyl (R)-3-chloro-3'-fluoro-4'-(1-(1-(2,2,2-trifluoroacetamido)cyclopropane-1-carboxamido)ethyl)-[1,1'-biphenyl]-2-carboxylate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

N-(2-hydroxyethyl)-2-((Z)-4,4,7-trifluoro-1-(4-((R)-2-fluoropropoxy)-2-(trifluoromethyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene)acetamide ( src )

N-Tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide ( src )

SOLUTOL (R) HS 15 ( src )

Sodium (R)-2-(2-amino-3-(1H-indol-3- yl)propanamido)-2-methylpropanoate-propan-2-ol ( src )

TEKPRINT ® SB 1010 N RED2 ( src )

eHDSI Terminologies, published by HL7 Europe. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/EHDSI-Terminology-package/ and changes regularly. See the Directory of published versions ( src )

External References

Unattributed Code Systems

Copyright Fragment

Copyright and Registered Trademark Uses

External References

Internal Images